GB0625100D0 - Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection - Google Patents
Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotectionInfo
- Publication number
- GB0625100D0 GB0625100D0 GBGB0625100.3A GB0625100A GB0625100D0 GB 0625100 D0 GB0625100 D0 GB 0625100D0 GB 0625100 A GB0625100 A GB 0625100A GB 0625100 D0 GB0625100 D0 GB 0625100D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- chemoprotection
- epigallocatechin
- gallate
- compositions
- cancer therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0625100.3A GB0625100D0 (en) | 2006-12-15 | 2006-12-15 | Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection |
PCT/IB2007/004363 WO2008075201A2 (en) | 2006-12-15 | 2007-12-17 | Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0625100.3A GB0625100D0 (en) | 2006-12-15 | 2006-12-15 | Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection |
Publications (1)
Publication Number | Publication Date |
---|---|
GB0625100D0 true GB0625100D0 (en) | 2007-01-24 |
Family
ID=37712247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0625100.3A Ceased GB0625100D0 (en) | 2006-12-15 | 2006-12-15 | Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0625100D0 (en) |
WO (1) | WO2008075201A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010014921A2 (en) | 2008-08-01 | 2010-02-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor antagonists and partial agonists |
WO2009123881A1 (en) | 2008-03-31 | 2009-10-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Purine derivatives as a3 receptor- selective agonists |
US8916570B2 (en) | 2008-03-31 | 2014-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists and antagonists |
US9181253B2 (en) | 2008-08-01 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists, partial agonists, and antagonists |
JP5842254B2 (en) * | 2010-06-23 | 2016-01-13 | 国立大学法人九州大学 | Combination of EGCG or methylated EGCG and PDE inhibitor |
EP2422815A1 (en) * | 2010-08-18 | 2012-02-29 | Grindeks, a joint stock company | Pharmaceutical composition of tegafur and natural flavonoid derivative catechin for potentiating antitumour effect and for treating tumours |
WO2018091447A1 (en) * | 2016-11-17 | 2018-05-24 | Bayer Pharma Aktiengesellschaft | Cancer treatment by glycerol-3-phosphate dehydrogenase 1 inhibition |
CN110832317B (en) * | 2017-06-13 | 2022-06-07 | 浙江海正甦力康生物科技有限公司 | Method for identifying tea quality |
CN112618550A (en) * | 2021-01-15 | 2021-04-09 | 中国医学科学院医药生物技术研究所 | Antineoplastic uracil compound and lipid composition thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1036260A (en) * | 1996-07-18 | 1998-02-10 | Mitsui Norin Kk | Enhancement of effect of anticancer agent |
IL133680A0 (en) * | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
US20040204481A1 (en) * | 2001-04-12 | 2004-10-14 | Pnina Fishman | Activation of natural killer cells by adenosine A3 receptor agonists |
AUPS312602A0 (en) * | 2002-06-21 | 2002-07-18 | James Cook University | Organ arrest, protection, preservation and recovery |
WO2006021888A2 (en) * | 2004-08-27 | 2006-03-02 | Universidad De Murcia | Dihydrofolate reductase inhibition by epigallocatechin gallate compounds |
-
2006
- 2006-12-15 GB GBGB0625100.3A patent/GB0625100D0/en not_active Ceased
-
2007
- 2007-12-17 WO PCT/IB2007/004363 patent/WO2008075201A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2008075201A3 (en) | 2009-01-29 |
WO2008075201A2 (en) | 2008-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL257681A (en) | Methods and compositions for treating cancer | |
HRP20160949T1 (en) | Novel compositions and methods for cancer treatment | |
IL190882A0 (en) | Compositions for cancer therapy | |
HK1133268A1 (en) | Compositions for diagnosing and treating cancer and uses thereof | |
HK1220989A1 (en) | Compositions comprising hmw-maa and fragments thereof for treating cancer hmw-maa | |
ZA200807934B (en) | Cancer treatments | |
EP1996612A4 (en) | Compositions for treatment of cancer | |
IL197389A0 (en) | Prophylactic or therapeutic agent for cancer | |
WO2007081751A9 (en) | Compositions and methods for the treatment of cancer | |
EP2049151A4 (en) | Methods and compositions for the treatment of cancer | |
EP2025347A4 (en) | Prophylactic and therapeutic agent for cancer | |
GB0625100D0 (en) | Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection | |
IL243294A0 (en) | Compounds and compositions for treatment of cancer | |
EP2005954B8 (en) | Kit for cancer therapy and pharmaceutical composition for cancer therapy | |
EP2150270A4 (en) | Methods and compositions for the treatment of cancer | |
EP1979487A4 (en) | Cobalamin compositions for the treatment of cancer | |
EP2018873A4 (en) | Prophylactic/therapeutic agent for cancer | |
EP1941909A4 (en) | Preventives/remedies for cancer | |
EP2099303A4 (en) | Therapeutic tetrahydroisoquinoline-based compositions for cancer therapy | |
GB0710871D0 (en) | Cancer treatment | |
EP2068629A4 (en) | Compositions and methods for treating cancer | |
PT3067054T (en) | Novel compositions and methods for cancer treatment | |
SI3067054T1 (en) | Novel compositions and methods for cancer treatment | |
GB0612259D0 (en) | Cancer therapeutic | |
GB0606702D0 (en) | Cancer therapeutic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |